Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants.
نویسندگان
چکیده
Inhibitors against Coagulation Factor VIII: Considerations on the Differentiation between the 2 Circulating Anticoagulants, Armando Tripodi, Maria Elisa Mancuso, Veena Chantarangkul, Marigrazia Clerici, Rossella Bader, Pier Luigi Meroni, Elena Santagostino, and Pier Mannuccio Mannucci ( Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, University and Foundation IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy; 2 IRCCS Istituto Auxologico Italiano, Milan, Italy; * address correspondence to this author at: Via Pace 9, 20122 Milan, Italy; fax 39-02-50320723, e-mail armando. [email protected])
منابع مشابه
Laboratory diagnosis of lupus anticoagulants.
Circulating anticoagulants or inhibitors of clotting factors are defined as endogenously produced substances that interfere with various in vitro tests of coagulation. Anticoagulants are usually immunoglobulins, although other endogenous materials, such as heparin or fibrinogen split products, may inhibit in vivo or in vitro coagulation (Table 1). Specific inhibitors are immunoglobulins with ep...
متن کاملNon-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors.
Dear Sirs, Individual coagulation factor inhibitors and lupus anticoagulants generally result in prolonged clotting times in coagulation assays. By far the most frequently occurring individual coagulation factor inhibitors are allo-antibodies against factor (F) VIII and FIX. These inhibitors arise in 10–30% of haemophilia A and 4–5% of haemophilia B patients treated with FVIII or FIX concentrat...
متن کاملFACTOR V AND VIII INHIBITOR IN PATIENTS WITH COMBINED FACTOR V AND VIII DEFICIENCY
Patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). In this survey we detected factor V and VIII inhibitor in ten patients with combined deficiency of factors V and VIII from north east of Iran (Khorassan province). It was revealed in our survey that eight patients had both factor V and factor VIII i...
متن کاملTechniques for demonstration of the specificity of circulating anticoagulants against antihemophilic factor (factor VIII), with studies of two cases possibly related to diphenylhydantoin therapy.
Circulating anticoagulants against antihemophilic factor (AHF, factor VIII) sometimes seem to inactivate other clotting factors as well. Measurements of the concentration of clotting factors in highly diluted plasma, or after neutralization of the anticoagulant with purified AHF, have demonstrated the specific nature of the anticoagulant in a patient under treatment with diphenylhydantoin. A se...
متن کاملStudies on a circulating anticoagulant in systemic lupus erythematosus: evidence for inhibition of the function of activated plasma thromboplastin antecedent (factor XIa).
Plasma proteins which interfere with blood coagulation have often been described in patients with systemic lupus erythematosus (SLE). The most frequent type interferes with the conversion of prothrombin to thrombin and thus prolongs the prothrombin time. Infrequently, SLE patients exhibit anticoagulants which appear to block the earlier stages of coagulation such as those involving factor VIII ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical chemistry
دوره 51 10 شماره
صفحات -
تاریخ انتشار 2005